Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
NCT01523171 · Bristol-Myers Squibb · PHASE2 · terminated · last registry update 2026-07-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Results posted on the registry: Jonsson Comprehensive Cancer Center, sorafenib tosylate (NCT01624285)
- 2026-10-21Results posted on the registry: The University of Texas Health Science Center at San Antonio, Sorafenib (SOR) + Hydroxychloroquine (HCQ) (NCT03037437)
- 2026-10-20Phase 3 first posted: Sun Yat-sen University, Benmelstobart + Anlotinib (NCT07881900)
- 2026-10-06Results posted on the registry: Bristol-Myers Squibb, SAR302503 (TG101348) (NCT00724334)
- 2026-09-23Phase 3 first posted: BeOne Medicines, BGB-B2033 + Lenvatinib (NCT07836530)
- 2026-08-25Also stopped (terminated): Association of Urologic Oncology (AUO), Sunitinib + Placebo (NCT01216371)
- 2026-08-17Also stopped (withdrawn): Thomas Jefferson University, Pacritinib + Azacitidine (NCT07387354)
- 2026-08-11Results posted on the registry: Bristol-Myers Squibb, SAR302503 + Placebo (NCT01437787)
- 2026-08-11Also stopped (terminated): Bristol-Myers Squibb, SAR302503 + Placebo (NCT01437787)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against FLT3 (NCT07712848)
- 2026-07-14Results posted on the registry: Jennerex Biotherapeutics, JX-594 + Sorafenib (NCT01171651)
- 2026-07-08Results posted on the registry: Jennerex Biotherapeutics, JX-594 recombinant vaccina GM-CSF (NCT01387555)
- 2026-05-26Also stopped (terminated): The University of Texas Health Science Center at San Antonio, bemcentinib + pacritinib (NCT06516887)
- 2026-04-17Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Fedratinib Pill (NCT05177211)
- 2026-03-30Results posted on the registry: HonorHealth Research Institute, Vemurafenib + Sorafenib (NCT05068752)
- 2026-03-18Phase 3 first posted: PETHEMA Foundation, Azacitidine + Venetoclax (NCT07478991)
- 2026-03-18Results posted on the registry: Nerviano Medical Sciences, NMS-03592088 (NCT03922100)
- 2026-03-18Also stopped (terminated): Nerviano Medical Sciences, NMS-03592088 (NCT03922100)
- 2026-03-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Gilteritinib + Sorafenib (NCT07463651)
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2026-02-12Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Gilteritinib + Azacitidine + Venetoclax + Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib (NCT07407140)
- 2026-02-03Phase 3 first posted: Fudan University, SHR-A1811 + Famitinib+SHR-A1811 (NCT07382687)
- 2026-01-05Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2026-01-05Also stopped (terminated): Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2025-12-24Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Sorafenib (NCT01658878)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision